Collaborations
Affimed has built a portfolio of novel therapeutic antibodies, based on the unique TandAb® platform, representing a potent alternative to existing IgG-based therapies.
Collaborations
Affimed is preparing to enter partnering deals and strategic alliances around its proprietary product candidates and its TandAb® technology platform RECRUIT-TandAb®, and BiBLOCK-TandAb®.
TandAbs® represent a unique and potent alternative to therapeutic monoclonal antibodies due to their four binding sites. TandAbs® possess the same avidity as IgGs but recognise two different targets. They possess an enhanced ADCC and an excellent safety profile. The long half-life of TandAbs® will allow convenient dosing schedules. Production in E.coli provides an attractive perspective regarding COGS. The multifaceted application possibilities make TandAb® antibodies an ideal match for oncology and inflammatory diseases.
Due to their manifold application possibilities and their superior features, the TandAb® molecules have the potential to become the “next generation” therapeutic antibodies. Affimed´s products either act as a RECRUIT-TandAb® via recruitment of immune effector cells, e.g., T-cells or NK-cells, or as “BiBLOCK” TandAb® via the dual inhibition of two targets, e.g., growth factors in the signalling pathway.
Based on its proprietary TandAb® technology platform, Affimed has generated a portfolio of innovative therapeutic antibody formats targeting attractive indications with high medical need. Our product candidates were selected against targets for which products are on the market or in advanced clinical development, such as CD19, CD30, CD3, EpCAM, EGFR and others.
Affimed plans to form partnerships based on its proprietary TandAb® platform and its product portfolio. A key strategy is to re-engineer existing antibodies into TandAbs® to achieve better and safer medicines. In addition, Affimed has access to fully human antibody libraries and, up to now has successfully generated more than 20 TandAb® antibody candidates.
